SEHK:3692Pharmaceuticals
Does Hansoh Pharmaceutical Group's (SEHK:3692) Ameile Label Expansion Reveal a Deeper Oncology Strategy Shift?
Earlier this month, Hansoh Pharmaceutical Group announced that China’s National Medical Products Administration approved an additional indication for its innovative lung cancer drug Ameile, allowing its use with pemetrexed and platinum-based chemotherapy as a first-line treatment for certain adult EGFR-mutated NSCLC patients, marking the drug’s fifth approved indication.
This latest approval meaningfully broadens Ameile’s clinical footprint in lung cancer, underscoring Hansoh’s focus on...